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Abstract
A better understanding of serological data and risk factors for coronavirus disease 2019 (COVID-19) infection in healthcare workers (HCWs) is
especially important in African countries where human resources and health services are more constrained. We reviewed and appraised the
evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence and its risk factors in HCWs in Africa to inform
response and preparedness strategies during the SARS-CoV-2 pandemic. We followed the Preferred Reporting Items for systematic reviews
and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines in this scoping review. Databases including PubMed, Embase and
preprint servers were searched accordingly from the start of the COVID-19 pandemic to 19 April 2021. Our search yielded 12 peer-reviewed and
four pre-print articles comprising data on 9223 HCWs from 11 countries in Africa. Seroprevalence varied widely and ranged from 0% to 45.1%.
Seropositivity was associated with older age, lower education, working as a nurse/non-clinical HCW or in gynaecology, emergency, outpatient or
surgery departments. Asymptomatic rates were high and half of the studies recommended routine testing of HCWs. This scoping review found
a varying but often high SARS-CoV-2 seroprevalence in HCWs in 11 African countries and identified certain risk factors. COVID-19 public health
strategies for policy and planning should consider these risk factors and the potential for high seroprevalence among HCWs when prioritizing
infection prevention and control measures and vaccine deployment.
Keywords: Scoping review, seroprevalence, Africa, COVID-19, SARS-CoV-2, health professionals
Key messages
• There are 16 articles on seroprevalence comprising data on
9223 HCWs from 11 countries in Africa.
• Seroprevalence varied widely and ranged from 0% to
45.1%.
• Seropositivity was associated with older age, lower educa-
tion, working as a nurse/non-clinical HCW, or in gynaecol-
ogy, emergency, outpatient, or surgery departments.
• COVID-19 policies should consider these risk aspects and
the partly high seroprevalence among HCWs when priori-
tizing IPC measures and vaccine deployment.
Introduction
The coronavirus disease 2019 (COVID-19) pandemic has
put health systems worldwide to an unprecedented test. As
frontline workers, healthcare workers (HCWs) are a criti-
cal part of the health system’s pandemic response and are
themselves at high risk of infection. Vaccine roll-out, therefor,
prioritizes HCWs worldwide (WHO, 2020b), and at the time
of writing, 35 African countries had begun vaccine campaigns
(Our World in Data, 2021).
Serological studies are investigations using serology test-
ing to look for antibodies in blood (Centers for Disease
Control and Prevention, 2021). These studies give insight
into the true burden of infection as they have the ability to
account for asymptomatic and unreported cases. These stud-
ies can provide data on infection trends, effects of interven-
tions, vaccine deployment prioritization guidelines (Maeda
and Nkengasong, 2021) and geographical distribution map-
ping for identification of populations at particularly high risk
(Peeling et al., 2020).
A previous systematic review on seroprevalence in HCWs
only included three African studies (Galanis et al., 2020).
Nevertheless, data on seroprevalence and risk factors are
specifically important in the African continent, where coun-
tries have predominantly lower access or quality of healthcare
(Our-World-in-Data, 2015). This region furthermore experi-
ences constrained human resources in healthcare. Compared
to Europe, where there are 80 nurses per 10 000 population,
across Africa there are only 10 (WHO, 2021a), emphasizing
the high need to protect this scare workforce. Evidence on the
implementation of measures that can help detect and mitigate
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exposures such as triage systems, dedicated COVID-19wards,
as well as surveillance testing and infection prevention and
control (IPC) availability is necessary to better understand the
risk of becoming overburdened.
This need is further emphasized in a region that does not
have ownership of vaccine production and must depend on
limited doses from other areas. Serological testing can also
provide guidance on vaccine decision-making.
This scoping review aimed to better understand and iden-
tify gaps in knowledge on seroprevalence of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) antibod-
ies in HCWs in the African continent and their risk factors
for COVID-19 infection, as well as how these seroprevalence
rates compare with the respective general population. The
added public health value of this review is that it provides the
most up to-date synthesis of all available research and hence
can inform public health strategies for policy and planning.
Materials and methods
Given the relative infancy and fast-moving pace of the field,
we selected a scoping review method without prior registra-
tion in a public domain.
Data sources and search strategy
This scoping review was performed according to the Preferred
Reporting Items for systematic reviews and Meta-Analyses
extension for Scoping Reviews (PRISMA-ScR) Checklist
(Tricco et al., 2018) and frameworks on scoping reviews
(Levac et al., 2010; Arksey and O’malley, 2005; Peters
Mdj et al., 2020) including the stages of (1) identifying a
research question, (2) identifying relevant studies, (3) study
selection, (4) charting the data and (5) summarizing and
reporting results. The detailed PRISMA checklist is available
in Supplementary Table S1.
We searched PubMed, Embase and preprint servers
(ArRvix, BioRvix, ChemRvix, MedRvix, Preprints.org,
ResearchSquare and SSRN) for designated terms for COVID-
19, seroprevalence, HCWs and African countries. The
complete search strategy is detailed in supplement 2. A
hand-search was also conducted to add relevant articles not
previously identified with the search strategy. Additionally,
to put the HCW seroprevalences into context, general pop-
ulation seroprevalences were gathered from the SeroTracker
database (Arora et al., 2021) for all countries included on 24
October 2021.
Selection and eligibility criteria
We screened title and abstracts of all publications returned
in the search, guided by pre-set inclusion and exclusion cri-
teria detailed as follows. We included articles published or
in preprint between the first detection of COVID-19 and 19
April 2021 on HCWs irrespective of prior COVID-19 sta-
tus or comorbidities in health settings in Africa with data
on serological status. We excluded reviews and evidence that
focused on non-HCWs or outside of Africa. HCWs were not
defined in this scoping review, but we followed the definition
of included studies, being mainly ‘clinical and non-clinical
care’. We did not restrict our search in terms of publica-
tion language, although search terms were all in English.
Two researchers independently undertook study selection,
and discussion resolved potential disagreement. Selection of
studies for general population seroprevalence was restricted
to the respective counties and overall study period.
Data extraction and quality assessment
Data from all selected studies were entered independently
by two researchers into a form created for this purpose in
Microsoft Excel. The following data were charted: author,
publication year, title, journal, publication status, study
period, city/country, sample size, sampling strategy, response
rate, inclusion criteria, exclusion criteria, study design, sex,
age, seroprevalence, asymptomatic rate, sample collection,
testing strategy, testing rate, type of antibody, type of test, test
name, factors investigated, factors associated, level of analysis
and additional data such as reported triage system, dedicated
COVID-19 wards, routine testing, IPC or personal protective
equipment (PPE) availability.
The quality of studies was assessed by two authors inde-
pendently using Joanna Briggs Institute (JBI) critical appraisal
tool for prevalence studies (Munn et al., 2015) adapted with
additional specifications (Arora et al., 2021). Bias levels were
assessed using a 9-point ranking system with categorization




The search identified a total of 102 articles; following the
removal of duplicates and critical assessment of title and
abstracts, 19 potentially relevant articles were identified for
full-text evaluation (Figure 1). Application of the pre-set
eligibility criteria resulted in a final inclusion of 16 articles.
Study characteristics
The included 16 studies contain seroprevalence data on 9223
HCWs from 11 countries across Africa: Democratic Repub-
lic of Congo (Mukwege et al., 2021), Egypt (Mostafa et al.,
2020; 2021; Abdelmoniem et al., 2021; Kassem et al., 2020;
Mukhtar et al., 2021), Kenya (Etyang et al., 2021), Libya
(Kammon et al., 2020), Malawi (Chibwana et al., 2020),
Mauretania (Salem et al., 2021), Nigeria (Majiya et al., 2020;
Olayanju et al., 2020), South Africa (Goldblatt et al., 2021),
Togo (Halatoko et al., 2020), Zambia (Fwoloshi et al., 2021)
and Zimbabwe (Rusakaniko et al., 2021) (Table 1).
Twelve articles were published in peer-reviewed journals
(Goldblatt et al., 2021; Halatoko et al., 2020; Abdelmoniem
et al., 2021; Kassem et al., 2020; Mostafa et al., 2020;
Olayanju et al., 2020; Mostafa et al., 2021; Mukwege et al.,
2021; Mukhtar et al., 2021; Salem et al., 2021; Fwoloshi
et al., 2021; Rusakaniko et al., 2021) and four were published
in preprint services (Chibwana et al., 2020; Kammon et al.,
2020; Majiya et al., 2020; Etyang et al., 2021). Twelve studies
used total population sampling, reflecting that all HCWs of a
given setting were included (Chibwana et al., 2020; Goldblatt
et al., 2021; Abdelmoniem et al., 2021; Kassem et al., 2020;
Mostafa et al., 2020; 2021; Etyang et al., 2021; Mukhtar
et al., 2021; Salem et al., 2021; Mukwege et al., 2021;
Fwoloshi et al., 2021; Rusakaniko et al., 2021) and four
reported to have used a random sampling strategy (Halatoko
et al., 2020; Kammon et al., 2020; Majiya et al., 2020;
Olayanju et al., 2020). All studies were conducted between
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Figure 1. Selection of sources of evidence
April and December of 2020 in hospital settings, with the
exception of two studies which did not report details on HCW
recruitment (Halatoko et al., 2020; Majiya et al., 2020).
Three studies took place in specific departments, such as
emergency (Abdelmoniem et al., 2021), paediatrics (Goldblatt
et al., 2021) or gastroenterology (Kassem et al., 2020). In six
studies, the percentage of males was higher than the percent-
age of females (Kammon et al., 2020; Abdelmoniem et al.,
2021; Majiya et al., 2020; Mukhtar et al., 2021; Mukwege
et al., 2021; Salem et al., 2021).
Reported sensitivity ranged from 71.1% (Mukwege et al.,
2021) to 100% (Goldblatt et al., 2021) and specificity from
85.0% (Halatoko et al., 2020) to 100% (Fwoloshi et al.,
2021; Mostafa et al., 2020; 2021; Mukwege et al., 2021).
More than 60% of the studies used tests that met the com-
monly set minimum performance criteria of sensitivity ≥90%
and test specificity >95% (Biocentury, 2020). Please see Sup-
plementary Table S5 for detailed information on all study and
antibody test characteristics discussed above.
Six studies assessed rates of asymptomatic infection, five
of which reported asymptomatic rates above 60% (Goldblatt
et al., 2021; Kassem et al., 2020; Mostafa et al., 2021; 2020).
Quality assessment
Following the JBI critical appraisal tool, studies were rated out
of a total of 9 points, and all were found to be of moderate-
to-low risk of bias (ranging between 5 and 8) (Supplemen-
tary Table S3). Risk of bias primarily arose from aspects
such as test characteristics or non-reporting of response rates
(Supplementary Table S3).
Seroprevalence and its geographic distribution
Seroprevalence among studies ranged from 0% to 45.1%,
with highest prevalence in Nigeria (45.1%) (Olayanju et al.,
2020) and DRC 41.2% (Mukwege et al., 2021) and lowest
in Libya, Togo and Egypt (0%, 1.4% and 1.3%, respec-
tively) (Kammon et al., 2020; Halatoko et al., 2020; Mostafa
et al., 2020). Data collection across countries started in April
2020 and ended in December 2020 (Table 1). Five studies
originated from Egypt, four of which were cross-sectional,
while one was a consecutive follow-up cohort study for one
of the three studies (Mostafa et al., 2021). The follow-up
cohort study found a seroconversion rate of 4% at a 3-week
interval (Mostafa et al., 2021), being 2.7 percentage points
higher than the baseline cross-sectional study finding of 1.3%
seroprevalence (Mostafa et al., 2020). The three other cross-
sectional studies found a prevalence of 12.2%, 18.2% and
31.0% among HCWs (Kassem et al., 2020; Abdelmoniem
et al., 2021; Mukhtar et al., 2021).
Risk factors
Ten studies investigated factors associated with seropositivity,
eight of which found association reported by odds ratio (OR)
or hazard ratio (HR) (Table 1).
Risk of seropositivity increased with age. This was shown
in detail in two studies from Egypt with the exemption of
age group 40–49 years [Mostafa et al., 2020: reference age:
18–24 years; 25–29 years, OR=3.9, confidence interval (CI)
0.96–16.1; 30–39 years, OR=4.3, CI 1.1–17.3; 40–49 years,
OR 2.8, CI 0.6–12.9; ≥50 years, OR=4.2, CI 0.8–21.2 and
Mostafa et al., 2021: reference age 18–29 years; 30–39 years,
HR=2.6, CI 1.3–4.9; 40–49 years, HR=2.4, CI 1.2–4.7;
≥50 years, HR=2.7, CI 1.3–5.6]. Sex was not associated
with seropositivity. Lower levels of education had higher
risks for seropositivity (reference education: university or
higher; secondary HR=2.0, CI 1.2–3.3; primary/preparatory
HR=3.9, CI 1.9–8.0; less than primary HR=3.3, CI 1.4–
7.8; Mostafa et al., 2021). Odds of seropositivity were higher
for HCWs in the operating room (OR=3.2, CI 1.3–8.0;
Mostafa et al., 2020), emergency department (OR=3.2,
CI 1.1–9.4; Olayanju et al., 2020), outpatient department
(OR=2.3, CI not reported; Rusakaniko et al., 2021) or
obstetrics and gynaecology department (OR=19.3, CI 2.0–
183.4; Olayanju et al., 2020). Two studies reported higher
risk of seropositivity for nurses (OR=4.7, CI 2.0–11.2;
OR=3.0, CI 1.6–5.5; reference group physicians, respec-
tively; Mostafa et al., 2020; 2021), and one study reported
higher risks for non-clinical HCWs (OR 7.8, CI 1.7–34.9,
reference group nurses; Fwoloshi et al., 2021).
4 Health Policy and Planning, 2021, Vol. 00, No. 0














Cairo, Egypt 06/2020 203 18.2 (13.2–
24.2)
NAa Demographics (age, gender), pro-
fession (occupation), exposure
(contact with case),





















NRb Demographics (age, gender), pro-
fession (occupation), exposure
(site, working in COVID unit),







07/2020 575 2.2 (0.5–3.9) NRb Demographics (age, gender),
profession (occupation), exposure
(district, health facility type, con-
tact, direct patient care, care for
confirmed COVID-19, travel, visit
of health facility, in-person atten-
dance at work/school, market visit,
transportation), medical condition























77 0 (0.0–4.7) NRb None NAa
Kassem et al.
(2020)
Cairo, Egypt 06/2020 74 12.2 (5.7–
21.8)
62.5 Demographics (age, gender), pro-
fession (occupation), exposure
(contact with case/suspect),















4040 1.3 (1.0–1.7) 68.2 Demographics (age, gender,




use), exposure (location of con-
tact with confirmed/suspected
case, duration, type of contact),







2282 4.0 (3.6–5.3) 64.0 Demographics (age, gender, resi-
dence, marital status, education),
profession (occupation), exposure
(location of contact with con-
firmed/suspected case, duration,
type of contact), medical condition
(comorbidities, pregnancy, tobacco
use), symptoms (severity, fever,
muscle pain, joint pain, sneezing,
shortness of breathing, other respi-
ratory symptoms, loss of appetite,







455 7.9 (5.8–10.8) 31.0 Demographics (age, gender), medical
condition (clinical history, med-

























77.7 Demographics (gender), profession
(occupation), exposure (type of
work, use of PPE, contact with







04/2020 133 45.1 (36.5–
54.0)







06/2020 635 26.1 (22.8–
29.7)








05/2020 853 1.7 (0.9–2.7) NRb None NAa
aNA: not applicable as the study excluded symptomatic HCWs.
bNR: not reported, bolded factors are those significantly associated with seropositivity.
Symptoms like fever, dry cough and change/loss of smell
were associated with seropositivity (Kassem et al., 2020;
Mostafa et al., 2020; 2021), with change/loss of smell having
the highest odds (OR=26.2, CI 2.1–329.7; Mostafa et al.,
2020). Medical conditions like pregnancy and chronic kid-
ney disease were associated with seropositivity (OR=3.5,
CI 1.1–11.9; OR=4.4, CI 1.0–19.0, respectively; Mostafa
et al., 2021). More than 15minutes of contact with a con-
firmed case were positively associated (OR=2.2, CI 1.2–4.1)
with seropositivity, whereby exposure at work was negatively
associated (OR=0.5, CI 0.3–0.8; Mostafa et al., 2021). No
association between seropositivity and use of IPC measures
could be found, but in-person attendance at work/school and
frequent market visits (3–5 visits/month) were found to be
risk factors (OR = 4.8, CI 1.6–13.9; OR=3.0, CI 1.3–7.0,
respectively; Fwoloshi et al., 2021).
Gap analysis
None of the studies reported facilities having a COVID-19
triage in place. Only one specified existence of dedicated
wards (Kassem et al., 2020) or that HCWs were specifically
trained in COVID-19 IPC measures (Fwoloshi et al., 2021).
Five studies raised concerns about insufficient PPE availabil-
ity or asked to increase supply (Majiya et al., 2020; Mukwege
et al., 2021; Etyang et al., 2021; Fwoloshi et al., 2021;
Rusakaniko et al., 2021), whereby one study asked for PPE
especially for HCWs with patient contact (Rusakaniko et al.,
2021). Fifty percent of included studies stated a lack of rou-
tine testing of HCWs or recommended its implementation due
to the high seroprevalence and asymptomatic rates.
General population seroprevalence comparison
Seroprevalence in the general population in the included coun-
tries ranged between 0% (Elfakhri et al., 2020) and 44.6%
(Marion et al., 2021). For four countries, there were no gen-
eral population data available: Malawi, Mauritania, Togo
and Zimbabwe. Seroprevalence in the other included coun-
tries ranged from 16.6% (Nkuba et al., 2021) to 40.8%
(Philippe et al., 2021) in DRC, from 29.8% (Girgis et al.,
2021) to 41.0% (Musa et al., 2021) in Egypt, from 1.3%
(Lucinde et al., 2021) to 34.7% (Ngere et al., 2021) in Kenya,
from 0% (Elfakhri et al., 2020) to 4.2% (Kammon et al.,
2020) in Libya, from 16.1% (Okpala et al., 2021) to 42.0%
(Ijeoma et al., 2021) in Nigeria, from 23% (Kleynhans et al.,
2021) to 44.6% (Marion et al., 2021) in South Africa and
from 2.1% (Mulenga et al., 2021) to 8.2% (Hines et al., 2021)
in Zambia.
Discussion
The overall seroprevalence among HCWs across 11 Africa
countries varied widely reflecting recent data from a system-
atic review of seroprevalence of anti-SARS-CoV-2 antibodies
in Africa, which combined the general population and specific
working groups (Chisale et al., 2021).
Direct comparison with the general population is challeng-
ing and was not the primary aim of the current manuscript,
but data available from the general population in the 11
included countries suggest highly varying seroprevalences
similar to those of HCWs with rates between 0% and 44.6%.
The seroprevalence amongHCWs could be influenced by vari-
ety of factors that may differ between levels (national and
local) and countries. National Public Health Institutes vary
widely in breadth and depth (Africa CDC, 2019), especially
inWest Africa, where the strengthening of public health struc-
tures (Meda et al., 2016) and surveillance is urgently needed
(Massinga Loembé et al., 2020). This need could be reflected
in the suspected underreporting of SARS-CoV-2 cases. The
Africa Centres for Disease Control and Prevention (CDC)
together with Ministries of Health have recognized this chal-
lenge and taken action with their joint continental Strategy
and the creation of Africa Task Force for Coronavirus (Africa
CDC, 2020).
HCWs in Africa are potentially more often in contact
with undiagnosed cases due to low surveillance and lim-
ited testing capacities (Chitungo et al., 2020). Furthermore,
the clinical COVID-19 diagnosis is even more challenging
due to other endemic febrile diseases such as malaria or
typhoid fever, which also act as competing priorities for front-
line HCWs (Maze et al., 2018). These competing priorities
make it difficult for hospitals to implement triage and infec-
tious disease treatment centres specifically dedicated for the
COVID-19 pandemic (Ayebare et al., 2020). This aspect is
reflected by the fact that only one included study reported
having a COVID-19 ward and none to have a triage system in
place.
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Additionally, even where cases are accurately diagnosed,
self-protection of HCWs is difficult due to IPC measure limi-
tations in infrastructure and equipment, such as overcrowded
settings (van de Ruit et al., 2020), in which proper distanc-
ing is more challenging and lacking supply or access to PPE
material (Desai et al., 2019). This lack of PPE availability or
the need for increased supply was confirmed by five of the
included studies. However, in contrast to studies in the UK or
USA (Nguyen et al., 2020), no significant association between
IPC and seropositivity among HCWs in Africa was shown in
our review (Abdelmoniem et al., 2021; Kassem et al., 2020;
Mukwege et al., 2021). This lack of association could arise
from the assessment procedure through questionnaire only.
Observation should be used in conjunction with question-
naires to realistically measure the impact of IPC on infection
mitigation (Sax et al., 2009).
The highest HCW prevalence rate was found in Nigeria
(45.1%) and supports reports that this country has Africa’s
second largest population incidence (WHO, 2021b) This high
rate was also reflected in the comparative general population
data that showed Nigeria to be second highest after South
Africa. Providing care with minimal precautionary measures
was a reported factor that is likely influencing high sero-
prevalence rates among HCWs in particular (Olayanju et al.,
2020).
Three of the included studies reporting a HCW seropreva-
lence <5%were conducted in April 2020, before the first wave
peaked in Africa (WHO, 2021b).
Detection and subsequent isolation of SARS-CoV-2 cases is
known to be especially challenging when asymptomatic rates
are high. In this scoping review, asymptomatic rates were
predominately >60% (Goldblatt et al., 2021; Kassem et al.,
2020; Mostafa et al., 2021; 2020; Mukwege et al., 2021) and
hence much higher than in a current meta-analysis (He et al.,
2020). These high asymptomatic rates warrant extra vigilance
in case detection strategies since asymptomatic HCWs can
not only infect their peers, colleagues and families but also
the vulnerable group of patients they are caring for. These
high asymptomatic rates are in particular worrisome in the
African region where continuous mass screening of HCWs is
rarely done, asymptomatic infections are broadly undetected
and hence HCWs are more likely to transmit the infections
onwards. Consecutively, half of the included studies recom-
mended the implementation of routine screening of HCWs to
avoid hidden onward transmission. Routine testing in practice
can hence mitigate the possibility of HCWs being a potential
source of infection to the vulnerable patients and protect the
scarce workforce of HCWs in low-resource settings.
In the African region, significant association was shown
between seropositivity and working in operating rooms,
obstetrics, outpatient clinic, gynaecology and emergency
department (Mostafa et al., 2020; Olayanju et al., 2020;
Rusakaniko et al., 2021). These risk areas are in accordance
with results from Denmark that found emergency units to be
a high-risk area (Iversen et al., 2020). One included study
found that nurses and non-clinical HCWs were at higher risk
of seropositivity than doctors (Mostafa et al., 2020), support-
ing our found association between seropositivity and lower
level of education or the non-prioritization for IPC trainings.
These associations show that non-clinical HCWs should also
be included in training regardless of their level of patient con-
tact. Interestingly, a study from Cairo found that exposure
to a confirmed case at home had a significantly higher HR
than exposure at work (Mostafa et al., 2021), suggesting
that HCWs’ non-occupational risk should also be consid-
ered. This finding supports the determined general population
seroprevalence range being similar to that of HCWs. Sero-
prevalence was associated with higher age in three included
studies (Rusakaniko et al., 2021; Mostafa et al., 2020; 2021),
which is concerning since higher age is known to be associated
with higher risk for severe disease (ECDC, 2021).
Limitations
There are several limitations in the present scoping review.
No grey literature of news and press releases were included.
We searched in databases and public preprint servers to assess
as much available scientific information as possible. As stud-
ies from only 11 countries could be identified, extrapolation
of findings to all HCWs in the African continent could not
be made. However, all African regions were represented,
although data on risk factors mainly stemmed from Egyptian
studies. Most studies used total population or random sam-
pling, and none of the studies were rated to be of high risk
of bias. No study explicitly included HCWs on sick leave or
in quarantine leading to a potential underestimation. A valid
and direct comparison between HCW and general population
seroprevalence rates was challenging as neither methods nor
timing of most studies were aligned.
Serological studies per se have some limitations. Given
antibody kinetics, infections can be undetectable for up to 2
weeks from the onset of infection or after 3months (Isho et al.,
2020). In addition to antibody kinetics, infection through
immunoglobulin G testing may also be undetected as some
individuals may not develop antibodies (Mostafa et al., 2021).
Overestimation, on the other hand, could be possible due
to cross-reactive antibodies that have been detected in sub-
Saharan Africa (Tso et al., 2020). Test characteristics and test
validity also affect seropositivity. Ten of the 16 studies used
tests that met the commonly set minimum performance crite-
ria of sensitivity ≥90% and test specificity >95% (Biocentury,
2020). These varying tests are leading to potentially divergent
results that stress the need for validation in study populations,
especially in African countries, where the concern of potential
lower specificity of SARS-CoV-2 commercial tests has been
raised (Nkuba Ndaye et al., 2021). Confirmation through
neutralizing antibody testing and interpretation with caution
has therefore been recommended (Nkuba Ndaye et al., 2021).
Public health contribution
To our knowledge, this is the first scoping review includ-
ing all preprint and published studies estimating seropreva-
lence and risk factors for SARS-CoV-2 seropositivity among
HCWs from 11 African countries with evidence appraisal.
The present scoping review has shown that data on sero-
prevalence in HCWs across the African continent are scarce
and hence data on risk factors even scarcer. Even though
there is no direct and valid comparison, this review offers the
first hint that differences between seroprevalences of HCWs
and the general population are not as prominent as in other
regions (Nguyen et al., 2020). Little standardization of study
protocols, including harmonization of tests, is done, and
consecutively, seroprevalence rates and risk factors are only
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marginally comparable between studies and countries. This
scoping review therefor stands as a roadmap to compiling
and understanding available data on the COVID-19 bur-
den in HCWs across Africa, a region in need for increased
investment in research (Guleid et al., 2021). This roadmap
provides themost up-to-date synthesis of all available research
and its gaps. It is a beneficial resource for larger projects
such as the planned representative national studies by the
Africa CDC (Maeda and Nkengasong, 2021) and surveil-
lance unity studies by the World Health Organization (WHO,
2020a). This serological data will help to assess the true
burden and risk factors among HCWs across the African
continent and hence provide knowledge to more strategi-
cally apply limited resources in response aspects such as IPC
measures and vaccine programmes. Furthermore, serological
data provides the possibility to make vaccination prioritiza-
tion more efficient with adaptations such as prioritization of
HCWs without detectible antibodies or single-dose vaccina-
tion of those who are seropositive (Krammer et al., 2021).
Such a strategic development of the vaccination programme
could better utilize limited vaccination resources given the
high seroprevalence rate of HCWs found in some African
countries.
Conclusion
This scoping review found a varying, but often high SARS-
CoV-2 seroprevalence among HCWs in the African region.
HCWs of older age and lower education, as well as nurses
and those working in gynaecology, emergency department,
outpatient clinic and operating rooms are at even higher risk.
These results point to a clear need to target specific risks of
HCWs, whether they arise due to their social position or
due to increased exposure of certain functions/settings within
the clinic. Further research is needed to better understand
which factors lead to increased risk of certain cadres of health
workers. Asymptomatic rates were high and half of the stud-
ies recommended routine testing of HCWs. Public health
strategies should take these risk aspects and the partly high
seroprevalence among HCWs into account when prioritizing
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